1 min read

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

On this page

Share

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

Related Articles

Explore posts connected to this topic

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and...

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

First clinical data from Phase 1 dose-escalation study in patients

Scaling Smarter: a Case Study in Overcoming Cell Therapy Manufacturing & Regulatory Hurdles

Cell & Gene Therapy Insights Webinar titled "Scaling Smarter: a